# Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

> **NCT00622505** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 121 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00622505
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-07
- **Primary completion:** 2012-04-03
- **Final completion:** 2012-04-03
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622505, "Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00622505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*